For Ben Sasse, Revolution Medicines’ pancreatic cancer trial felt like his best, only option

Revolution Medicines' daraxonrasib has shown remarkable results in a Phase 3 trial for advanced pancreatic cancer, extending median survival to 13.2 months versus 6.7 on chemo.